Avenue Therapeutics (ATXI) Stock Forecast, Price Target & Predictions
ATXI Stock Forecast
Avenue Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 327.05% upside from ATXI’s last price of $2.81) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ATXI Price Target
The average price target for Avenue Therapeutics (ATXI) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 327.05% upside from ATXI's last price of $2.81.
ATXI Analyst Ratings
According to 1 Wall Street analysts, Avenue Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ATXI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Avenue Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Jason McCarthy | Maxim Group | $12.00 | $3.39 | 253.98% | 327.05% |
The latest Avenue Therapeutics stock forecast, released on Jun 07, 2024 by Jason McCarthy from Maxim Group, set a price target of $12.00, which represents a 253.98% increase from the stock price at the time of the forecast ($3.39), and a 327.05% increase from ATXI last price ($2.81).
Avenue Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $2.81 | $2.81 | $2.81 |
| Upside/Downside | -100.00% | -100.00% | 327.05% |
In the current month, the average price target of Avenue Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avenue Therapeutics's last price of $2.81. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 07, 2024 | Maxim Group | Buy | Buy | Hold |
Avenue Therapeutics's last stock rating was published by Maxim Group on Jun 07, 2024. The company gave ATXI a "Buy" rating, the same as its previous rate.
Avenue Therapeutics Financial Forecast
Avenue Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Avenue Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ATXI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Avenue Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict ATXI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Avenue Therapeutics's previous annual EBITDA (undefined) of $NaN.
Avenue Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-1.12M | $-1.05M | $-1.17M |
| High Forecast | $-1.12M | $-1.05M | $-1.17M |
| Low Forecast | $-1.12M | $-1.05M | $-1.17M |
| Surprise % | - | - | - |
Avenue Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATXI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Avenue Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Avenue Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ATXI last annual SG&A of $NaN (undefined).
Avenue Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-1.00 | $-0.94 | $-1.05 |
| High Forecast | $-1.00 | $-0.94 | $-1.05 |
| Low Forecast | $-1.00 | $-0.94 | $-1.05 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Avenue Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATXI previous annual EPS of $NaN (undefined).
ATXI Forecast FAQ
Is Avenue Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Avenue Therapeutics (ATXI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ATXI's total ratings.
What is ATXI's price target?
Avenue Therapeutics (ATXI) average price target is $12 with a range of $12 to $12, implying a 327.05% from its last price of $2.81. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Avenue Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ATXI stock, the company can go up by 327.05% (from the last price of $2.81 to the average price target of $12), up by 327.05% based on the highest stock price target, and up by 327.05% based on the lowest stock price target.
Can Avenue Therapeutics stock reach $4?
ATXI's average twelve months analyst stock price target of $12 supports the claim that Avenue Therapeutics can reach $4 in the near future.
What are Avenue Therapeutics's analysts' financial forecasts?
ATXI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-3.342M (high $-3.342M, low $-3.342M), average SG&A $0 (high $0, low $0), and average EPS is $-2.99 (high $-2.99, low $-2.99).